Gather wisdom to overcome barriers: Well-designed nano-drug delivery systems for treating gliomas

Cui, Jiwei; Xu, Yuanxin; Tu, Haiyan; Zhao, Huacong; Wang, Honglan; Di, Liuqing; Wang, Ruoning

doi:10.1016/j.apsb.2021.08.013

Cited by 29 publications

(15 citation statements)

References 256 publications

(369 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes are a type of EVs, containing components from the parent cell such as DNA, RNA, lipids, proteins, etc. 227 Besides, exosomes possess natural composition, low immunogenicity, reduced cytotoxicity, favorable penetration through physiological barriers, and tumor cell-derived exosomes exhibit specific targeting towards parent tumor cells 228 . Also, extra characteristics and smart functions could be endowed on exosomes with ligand modification, cargo loading, etc.…”

Section: Carrier-based Smart Drug Deliverymentioning

confidence: 99%

Smart drug delivery systems for precise cancer therapy

Wang

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Carrier-based Smart Drug Deliverymentioning

confidence: 99%

Smart drug delivery systems for precise cancer therapy

Wang

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…Liposomes are spherical vesicles with a bilayer membrane composed of phospholipids and cholesterol. A number of liposomal formulations including PEGylated liposomal doxorubicin (NCT00944801), cationic liposome (SGT-53, NCT02340156), nanoliposome (CPT-11, NCT00734682), and immunoliposome (C225-ILs-dox, NCT03603379) have been investigated and successfully advanced to clinical trials to enable treatment of GBM …”

Section: Nanomedicine-based Therapies Targeting Glioma Stem Cellsmentioning

confidence: 99%

Nanomedicines Targeting Glioma Stem Cells

Sabu

Liu

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Glioblastoma (GBM), classified as a grade IV glioma, is a rapidly growing, aggressive, and most commonly occurring tumor of the central nervous system. Despite the therapeutic advances, it carries an ominous prognosis, with a median survival of 14.6 months after diagnosis. Accumulating evidence suggests that cancer stem cells in GBM, termed glioma stem cells (GSCs), play a crucial role in tumor propagation, treatment resistance, and tumor recurrence. GSCs, possessing the capacity for self-renewal and multilineage differentiation, are responsible for tumor growth and heterogeneity, leading to primary obstacles to current cancer therapy. In this respect, increasing efforts have been devoted to the development of anti-GSC strategies based on targeting GSC surface markers, blockage of essential signaling pathways of GSCs, and manipulating the tumor microenvironment (GSC niches). In this review, we will discuss the research knowledge regarding GSC-based therapy and the underlying mechanisms for the treatment of GBM. Given the rapid progression in nanotechnology, innovative nanomedicines developed for GSC targeting will also be highlighted from the perspective of rationale, advantages, and limitations. The goal of this review is to provide broader understanding and key considerations toward the future direction of GSC-based nanotheranostics to fight against GBM.

show abstract

“…Brain tumor is still one of the most difficult tumors to treat with nanomaterial-based drug delivery systems, due to the impedance of blood‒brain barrier 126 . However, attempts have been made to adequately map the boundaries of brain tumors.…”

Section: Tumors Types In Boundary Mappingmentioning

confidence: 99%